Objective: To establish an analytical method for the determination of puerarin in dog plasma with HPLC-FLD

and to evaluate the pharmacokinetics and relative-bioavailability of puerarin of tested multi-absorption enhancer and puerarin tablet after a single oral dose in healthy dogs. Method: Six healthy dogs took muti-absorption enhancer and puerarin tablets with a single oral dose in a randomized cross-over design in the case. The serum concentration of puerarin was determined by HPLC-FLD method. Result: The puerarin in test and reference formulations were Cmax (0.326±0.121) and (0.272±0.083) ng ·mL-1

tmax (2.750±0.957) and (4.500±1.732) h

t1/2α (1.157±0.748) and (1.223±0.311) h

t1/2β (6.679±2.552) and (1.987±0.386) h

AUC(0-t) (2.513±1.046) and (1.951±0.442) mg ·h ·L-1

AUC(0-∞) (5.035±2.190) and (3.001±1.382) mg ·h ·L-1

respectively. The relative bioavailability of puerarin was (128.8±31.2)%. Cmax

AUC(0-t) and AUC(0-∞) were not bioequivalent through the bioequivalent tests. Conclusion: The method is proved to be accurate

sensitive and rapid. Puerarin in the test formulation is not bioequivalent to the reference formulation. The relative-bioavailability of puerarin of tested multi-absorption enhancer and puerarin tablet is enhanced by 28.8 percents.